#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cardiac amyloidosis Cardiac failure acute Mixed-type liposarcoma Central nervous system lymphoma Progressive supranuclear palsy Head and neck cancer Juvenile psoriatic arthritis Gestational trophoblastic tumour Palmar-plantar erythrodysaesthesia syndrome Chondrosarcoma metastatic Arrhythmia Adrenogenital syndrome Tuberous sclerosis complex B-cell small lymphocytic lymphoma Retinal artery occlusion More trials…

    Learn about Rare Diseases

    Osteosarcoma recurrent – Trials in Disease Angiosarcoma – Basic Information Angelman’s syndrome – Diagnostics Burkitt’s lymphoma Myelodysplastic syndrome – Diagnostics Angiosarcoma recurrent Turner’s syndrome – Basic Information Leiomyosarcoma metastatic – Life with Disease Pemphigus – Diagnostics Rhabdomyosarcoma recurrent – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    BMS-986365 Cobimetinib Mitapivat Piperacillin Sodium Pp1815 Acemetacin Tamibarotene Solrikitug Eptacog Alfa (Activated) Padeliporfin Xenon Gskvx000000008866 Methylprednisolone Aceponate Cabotegravir Asciminib Paclitaxel Obaluronate Nizaracianine Triflutate Selpercatinib Mometasone Furoate Jnj-81241459 More therapies…

    Learn about Your Condition

    Acute promyelocytic leukaemia Body mass index increased Osteogenesis imperfecta Thromboembolectomy Dilated cardiomyopathy Paedophilia Intestinal ischaemia Post procedural oedema Neonatal respiratory failure Hepatotoxicity Substance use disorder Premature baby Vascular dementia Short stature Renal cell carcinoma stage IV More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina…

Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie

Ul. Fryderyka Szopena 2, Rzeszow, 35-055, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Remibrutinib for Adults with Chronic Inducible Urticaria Uncontrolled by H1-Antihistamines

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Cold urticaria
    Investigated Drugs:
    • Remibrutinib
    France Germany Hungary Italy The Netherlands Poland +4

  • Study Comparing BP11 and Omalizumab for Patients with Chronic Spontaneous Urticaria Resistant to H1 Antihistamines

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Omalizumab
    Bulgaria Hungary Latvia Lithuania Poland Slovakia

  • Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

    Not recruiting

    3 1
    Investigated Drugs:
    • Anifrolumab
    Austria Bulgaria Denmark France Germany Greece +7

  • Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Nemolizumab
    Austria Belgium Bulgaria Czechia Estonia France +8

  • Study on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neurodermatitis
    Investigated Drugs:
    • Nemolizumab
    Austria Belgium Denmark France Germany Hungary +5

  • Study of N-Acetyl-GED-0507-34-LEVO 5% gel applied daily for 12 weeks in patients with acne vulgaris

    Not recruiting

    3 1
    Investigated Drugs:
    • (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
    Italy Poland Spain

  • Title: Long-term safety study of N-Acetyl-GED-0507-34-LEVO gel 5% applied to the skin for patients with acne vulgaris

    Not recruiting

    3 1 1
    Investigated Drugs:
    • (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
    Italy Poland Spain

  • Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    4 1 1
    Investigated Drugs:
    • Tralokinumab
    Belgium Croatia Czechia Denmark Germany Ireland +6

  • Study on Rezpegaldesleukin for Treating Severe Alopecia Areata in Adults

    Not recruiting

    2 1
    Investigated Drugs:
    • Rezpegaldesleukin
    Poland

  • Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Bulgaria Croatia Germany Hungary Italy Lithuania +4
Previous Page
1 … 4 5 6 7 8 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!